RT Journal Article
SR Electronic
T1 Serum neurofilament light as a biomarker for prognosis in patients with newly diagnosed Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.01.21265751
DO 10.1101/2021.11.01.21265751
A1 Vijiaratnam, Nirosen
A1 Lawton, Michael
A1 Heslegrave, Amanda
A1 Guo, Tong
A1 Tan, Manuela MX
A1 Jabbari, Edwin
A1 Real, Raquel
A1 Woodside, John
A1 Grosset, Katherine A
A1 Chelban, Viorica
A1 Athauda, Dilan
A1 Girges, Christine
A1 Barker, Roger A
A1 Hardy, John
A1 Wood, Nicholas
A1 Houlden, Henry
A1 Williams, Nigel M
A1 Ben-Shlomo, Yoav
A1 Zetterberg, Henrik
A1 Grosset, Donald G
A1 Foltynie, Thomas
A1 Morris, Huw R
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/11/02/2021.11.01.21265751.abstract
AB Background Patients with Parkinson’s disease (PD) have variable disease progression. More accurate prediction of progression could improve clinical trial design. Although some variance in clinical progression can be predicted by age at onset and phenotype, we hypothesise that this can be improved by blood biomarkers.Objective To determine if serum neurofilament light (NfL) is a useful biomarker for prognostic modelling in PD.Methods We evaluated the relationship between serum NfL and baseline and longitudinal clinical measures as well as patients’ genetic (GBA and APOE) status in a large clinical dataset. We classified patients as having a favourable or an unfavourable outcome based on a previously validated model and explored whether serum NfL could distinguish prognostic phenotypes. We compared NfL with baseline candidate predictor variables and studied the combination of clinical, serum and genetic data.Results Serum NfL was associated with patients’ cognitive status at baseline. Baseline NfL was associated with the progression of motor and functional impairment and with increased mortality (Survival HR 1.85, CI: 1.03-3.33, p=0.04). Baseline NfL levels predicted unfavourable progression to a similar extent as previously validated clinical predictors (AUC: 0.74 vs 0.78, p=0.22). The combination of clinical, genetic and biomarker data produced a strong predication of unfavourable outcomes as compared to age and gender alone (AUC: 0.71-age/gender vs 0.83-ALL p = 0.0076)Conclusions Baseline serum NfL provides an objective measure of neurodegeneration in PD patients. Clinical trials of disease-modifying therapies might usefully stratify patients according using clinical, genetic and NfL status at the time of recruitment.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://dx.doi.org/10.17504/protocols.io.bzbep2je https://dx.doi.org/10.17504/protocols.io.by9ypz7w https://dx.doi.org/10.17504/protocols.io.bzd7p29n Funding StatementCohort studies: Tracking Parkinsons is primarily funded and supported by Parkinsons UK. It is also supported by the National Institute for Health Research (NIHR) Dementias and Neurodegenerative Diseases Research Network (DeNDRoN). This research was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and Cambridge BRC. The UCL Movement Disorders Centre is supported by the Edmond J. Safra Philanthropic Foundation. Genetic and biomarker analysis: Work on the genetics and biomarkers of progression in Parkinsons and related disorders is supported by Parkinsons UK (PhD Studentship to Dr Tan H-1703 Understanding and predicting Parkinsons progression) and the PSP Association. The study is funded by the joint efforts of The Michael J. Fox Foundation for Parkinsons Research (MJFF) and the Aligning Science Across Parkinsons (ASAP) initiative. MJFF administers the grant [Grant ID: ASAP-000478] on behalf of ASAP and itself. For the purpose of open access the author has applied a CC-BY public copyright license to the Author Accepted Manuscript (AAM) version arising from this submission. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Tracking Parkinsons study (REC Reference: 11/AL/0163) and PROSPECT (REC Reference: 14/LO/1575) studies have multicentre research ethics committee approvalsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors